PY1977703A - Piridazinonas y sus métodos de uso - Google Patents

Piridazinonas y sus métodos de uso

Info

Publication number
PY1977703A
PY1977703A PY201901977703A PY1977703A PY1977703A PY 1977703 A PY1977703 A PY 1977703A PY 201901977703 A PY201901977703 A PY 201901977703A PY 1977703 A PY1977703 A PY 1977703A PY 1977703 A PY1977703 A PY 1977703A
Authority
PY
Paraguay
Prior art keywords
methods
pyridazinones
formula
compounds
disclosed
Prior art date
Application number
PY201901977703A
Other languages
English (en)
Inventor
P Harmange Jean-Christophe
W Ledeboer Mark
H Daniels Matthew
Maolin Yu
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of PY1977703A publication Critical patent/PY1977703A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de acuerdo con la Fórmula (I) y composiciones farmacéuticas relacionadas. También se divulgan métodos terapéuticos, por ejemplo, para tratar enfermedades renales, usando los compuestos de Fórmula (I).
PY201901977703A 2018-09-18 2019-09-18 Piridazinonas y sus métodos de uso PY1977703A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732728P 2018-09-18 2018-09-18
US201862780553P 2018-12-17 2018-12-17

Publications (1)

Publication Number Publication Date
PY1977703A true PY1977703A (es) 2020-06-19

Family

ID=69887813

Family Applications (1)

Application Number Title Priority Date Filing Date
PY201901977703A PY1977703A (es) 2018-09-18 2019-09-18 Piridazinonas y sus métodos de uso

Country Status (35)

Country Link
US (3) US10654850B2 (es)
EP (2) EP3852533B8 (es)
JP (2) JP7474243B2 (es)
KR (2) KR20250171415A (es)
CN (1) CN112911935A (es)
AU (2) AU2019344928B2 (es)
BR (1) BR112021004926A2 (es)
CA (1) CA3113236A1 (es)
CL (1) CL2021000648A1 (es)
CO (1) CO2021004789A2 (es)
DK (1) DK3852533T3 (es)
EC (1) ECSP21026485A (es)
ES (1) ES2982498T3 (es)
FI (1) FI3852533T3 (es)
HR (1) HRP20240707T1 (es)
HU (1) HUE067188T2 (es)
IL (1) IL281438B2 (es)
LT (1) LT3852533T (es)
MA (1) MA71645A (es)
MD (1) MD3852533T2 (es)
MX (1) MX2021003152A (es)
MY (1) MY208106A (es)
PE (2) PE20250453A1 (es)
PH (1) PH12021550443A1 (es)
PL (1) PL3852533T3 (es)
PT (1) PT3852533T (es)
PY (1) PY1977703A (es)
RS (1) RS65558B1 (es)
SG (1) SG11202102053VA (es)
SI (1) SI3852533T1 (es)
SM (1) SMT202400201T1 (es)
TW (2) TWI894724B (es)
UA (1) UA128841C2 (es)
UY (1) UY38377A (es)
WO (1) WO2020061162A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
CN112911935A (zh) 2018-09-18 2021-06-04 金翅雀生物公司 哒嗪酮及其使用方法
CN113939295B (zh) * 2019-03-20 2025-05-16 金翅雀生物公司 哒嗪酮及其使用方法
WO2020206623A1 (en) 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
CA3136632A1 (en) 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
AR122450A1 (es) * 2020-05-08 2022-09-14 Lilly Co Eli Compuestos de (trifluorometil)pirimidin-2-amina
WO2022006278A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Reducing fibrosis and treating related diseases, disorders, and conditions
EP4174069A4 (en) * 2020-07-03 2024-07-10 Wuhan LL Science and Technology Development Co., Ltd. HETEROCYCLIC COMPOUND AND ASSOCIATED USE
US20240317755A1 (en) * 2021-02-07 2024-09-26 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound, and intermediate thereof, preparation method therefor and use thereof
EP4400500A4 (en) * 2021-09-10 2025-08-13 Medshine Discovery Inc HALOGEN-SUBSTITUTED PYRIDAZINONE COMPOUND AND ITS APPLICATION
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
CA2553969A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP4705922B2 (ja) 2004-01-29 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体拮抗薬
DE102004044231A1 (de) 2004-09-14 2006-03-16 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
UA95644C2 (ru) 2006-07-25 2011-08-25 Сефалон, Инк. Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
JP2010521463A (ja) 2007-03-15 2010-06-24 シェーリング コーポレイション グルカンシンターゼの阻害剤として有用なピペラジン置換ビリダジノン誘導体
RU2010121763A (ru) * 2007-10-31 2011-12-10 Ниссан Кемикал Индастриз, Лтд. (Jp) Производные пиридазинона и ингибиторы р2х7 рецептора
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
BR112013007499A2 (pt) * 2010-09-01 2016-07-12 Genentech Inc piridazinonas - métodos de criação e usos
JP6215315B2 (ja) * 2012-06-12 2017-10-18 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
JP6667093B2 (ja) 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
CN112911935A (zh) * 2018-09-18 2021-06-04 金翅雀生物公司 哒嗪酮及其使用方法
CN113939295B (zh) * 2019-03-20 2025-05-16 金翅雀生物公司 哒嗪酮及其使用方法
WO2020206623A1 (en) * 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
CA3136632A1 (en) * 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置

Also Published As

Publication number Publication date
KR20250171415A (ko) 2025-12-08
PT3852533T (pt) 2024-05-31
TWI828758B (zh) 2024-01-11
SI3852533T1 (sl) 2024-10-30
LT3852533T (lt) 2024-06-10
SMT202400201T1 (it) 2024-07-09
UY38377A (es) 2020-04-30
EP3852533B1 (en) 2024-02-28
DK3852533T3 (da) 2024-05-27
AU2019344928A1 (en) 2021-04-29
EP3852533B8 (en) 2024-07-17
PE20250453A1 (es) 2025-02-19
US10654850B2 (en) 2020-05-19
AU2025238155A1 (en) 2025-10-23
PL3852533T3 (pl) 2024-09-16
TW202430524A (zh) 2024-08-01
CN112911935A (zh) 2021-06-04
ECSP21026485A (es) 2021-07-30
JP2022500359A (ja) 2022-01-04
RS65558B1 (sr) 2024-06-28
CO2021004789A2 (es) 2021-07-30
TW202035402A (zh) 2020-10-01
ES2982498T3 (es) 2024-10-16
JP7474243B2 (ja) 2024-04-24
IL281438A (en) 2021-04-29
CL2021000648A1 (es) 2021-08-06
EP3852533A4 (en) 2022-06-15
EP4414365A1 (en) 2024-08-14
JP2024099595A (ja) 2024-07-25
HRP20240707T1 (hr) 2024-10-11
HUE067188T2 (hu) 2024-10-28
PH12021550443A1 (en) 2021-12-06
TWI894724B (zh) 2025-08-21
US20200283437A1 (en) 2020-09-10
FI3852533T3 (fi) 2024-05-24
BR112021004926A2 (pt) 2021-06-01
IL281438B1 (en) 2023-08-01
EP3852533A1 (en) 2021-07-28
AU2019344928B2 (en) 2025-07-03
CA3113236A1 (en) 2020-03-26
MY208106A (en) 2025-04-15
UA128841C2 (uk) 2024-11-06
US20200102301A1 (en) 2020-04-02
SG11202102053VA (en) 2021-04-29
KR102890905B1 (ko) 2025-11-24
MD3852533T2 (ro) 2024-08-31
US11046690B2 (en) 2021-06-29
MX2021003152A (es) 2021-06-23
WO2020061162A1 (en) 2020-03-26
KR20210069652A (ko) 2021-06-11
IL281438B2 (en) 2023-12-01
PE20211774A1 (es) 2021-09-08
US20220024917A1 (en) 2022-01-27
MA71645A (fr) 2025-05-30

Similar Documents

Publication Publication Date Title
CO2021004789A2 (es) Piridazinonas y sus métodos de uso
JOP20230318A1 (ar) مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
CO2018004124A2 (es) Compuestos heterocíclicos
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
MX2016014248A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
EA201691302A1 (ru) Новые гетероциклические соединения
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201792258A1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
BR112018012177A2 (pt) ?moduladores de hidantação de canais kv 3?
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
MX2024010216A (es) Compuestos de tienopirrolotriazina, su preparacion y su uso terapeutico.